3D reconstruction of resected retroperitoneal sarcoma tumour bed and ex vivo specimen.

ANZ J Surg

Division of Cancer Surgery, Peter MacCallum Cancer Centre, and Sir Peter MaCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.

Published: March 2025

Purpose: Retroperitoneal sarcomas (RPS) present a surgical challenge due to their complex anatomical relationships to organs and vascular structures. In this limited case series, we reconstructed the tumour beds of four cases of RPS and their ex vivo specimens.

Methods: Four patients underwent surgical resection of their retroperitoneal sarcoma at our centre in 2023-2024. After completing the tumour resection, a smartphone was utilized to capture images of both the tumour bed and the resected specimen. Images were imported into 3D reconstruction programs, which used artificial intelligence (AI) to reconstruct the 3D model, available to explore from various angles and sizes by the surgical team.

Results: Four patients were treated at our centre: two left-sided and two right-sided RPS. Pathology was liposarcoma in two patients and leiomyosarcoma in the other two. After the resection was completed, a smartphone was used to create the 3D model. A total of nine models were created, five models of the tumour bed and four models of the ex vivo specimen. Fixed structures present in both the tumour bed and the resected specimen were labelled in both models to allow orientation. These included the ureteric stump, the divided peritoneal reflection and the divided renal pedicle.

Conclusions: This technology has great potential for use in education, surgical quality control and other applications in surgical oncology.

Download full-text PDF

Source
http://dx.doi.org/10.1111/ans.70089DOI Listing

Publication Analysis

Top Keywords

tumour bed
16
retroperitoneal sarcoma
8
vivo specimen
8
bed resected
8
resected specimen
8
tumour
6
surgical
5
reconstruction resected
4
resected retroperitoneal
4
sarcoma tumour
4

Similar Publications

Purpose: The FAST-Forward study paved the way for ultrahypofractionation (UHF) in breast cancer. We prospectively registered and analyzed our case series receiving UHF + simultaneous integrated boost (SIB) to further reduce the treatment to a total of 5 days. The study aimed to present the 6-month early side effects results of the first patients treated with this scheme in 16 radiation oncology centers in Spain.

View Article and Find Full Text PDF

3D reconstruction of resected retroperitoneal sarcoma tumour bed and ex vivo specimen.

ANZ J Surg

March 2025

Division of Cancer Surgery, Peter MacCallum Cancer Centre, and Sir Peter MaCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.

Purpose: Retroperitoneal sarcomas (RPS) present a surgical challenge due to their complex anatomical relationships to organs and vascular structures. In this limited case series, we reconstructed the tumour beds of four cases of RPS and their ex vivo specimens.

Methods: Four patients underwent surgical resection of their retroperitoneal sarcoma at our centre in 2023-2024.

View Article and Find Full Text PDF

Context: Cells derived from neural crest populate several organs. A particular precursor cell, sympathogonia, gives rise to pheochromoblasts and neuroblasts. Due to common origin, tumors originating from pheochromoblasts, such as pheochromocytoma (PHEO) and paraganglioma (PGL), may rarely coexist with ganglioneuroma (GN).

View Article and Find Full Text PDF

Breast cancer preclinical models: a vital resource for comprehending disease mechanisms and therapeutic development.

EXCLI J

February 2025

Interdisciplinary Center for Innovation in Biotechnology and Neuroscience, Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, 10250, Sri Lanka.

A significant obstacle in translating innovative breast cancer treatments from bench to bed side is demonstrating efficacy in preclinical settings prior to clinical trials, as the heterogeneity of breast cancer can be challenging to replicate in the laboratory. A significant number of potential medicines have not progressed to clinical trials because preclinical models inadequately replicate the complexities of the varied tumor microenvironment. Consequently, the variety of breast cancer models is extensive, and the selection of a model frequently depends on the specific inquiry presented.

View Article and Find Full Text PDF

Background: Relapsed/refractory pediatric CNS tumors have a poor prognosis. EGFR is commonly overexpressed, but EGFRvIII mutations are uncommon. To target these tumors, we used chimeric antigen receptor (CAR) T cells with a binder based on mAb806 which recognizes ectopically expressed wild-type EGFR and EGFRvIII.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!